ESC 2026: Congress brings key readouts across the cardiovascular space
Clinical Trials Arena shares its top research picks from day one and two of the ESC 2026 congress.
Therapy Area
Amgen-AstraZeneca’s Tezspire nets another Phase III inflammatory disease win
Akeso logs Phase III success in second tumour type for ivonescimab
Surveillance and vaccine could protect against higher cancer risk from Lynch syndrome
Milestone’s etripamil nasal spray enters Phase III trial for atrial fibrillation
Orum to begin Phase I trial of ORM-1153 after FDA clearance
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
The changing landscape of childhood infectious disease in the US
